Slow adoption of GHTF guidelines by founding member nations offsets achievements
This article was originally published in SRA
Progress the Global Harmonization Task Force has made in framing a universally acceptable medical devices regulatory framework is not having the desired impact because of the perception that the organisation’s founding member jurisdictions - the US, the European Union, Japan, Australia and Canada - are slow to adopt the GHTF approach into their own existing regulations1.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.